Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Exelixis, Inc.
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Number of employees : 617 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Product619.2872.5%759.9578.5% +22.72%
License192.1922.5%161.3016.7% -16.07%
Research and Development Service39.504.6%49.975.2% +26.49%
Other Collaboration2.860.3%-3.44-0.4%-
Sales per region
2019
USD (in Million)%
United States770.2479.6%
Europe152.7715.8%
Japan44.764.6%
Managers
NameAgeSinceTitle
Michael Morrissey582010President, Chief Executive Officer & Director
Stelios Papadopoulos701998Chairman
Christopher J. Senner512015Chief Financial & Accounting Officer, Executive VP
Gisela M. Schwab, Dr.622016Chief Medical Officer & President-Medical Affairs
Peter Lamb, Dr.582016Chief Scientific Officer & EVP-Scientific Strategy
Jack L. Wyszomierski632004Independent Director
George H. Poste, Dr.742004Independent Director
Charles M. Cohen, Dr.681995Independent Director
Lance Willsey, Dr.571997Independent Director
Vincent T. Marchesi, Dr.832001Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 308,995,819 298,823,052 96.7% 0 0.0% 96.7%
Shareholders
NameEquities%
The Vanguard Group, Inc. 28,317,428 9.16%
Renaissance Technologies LLC 23,006,910 7.45%
Capital Research & Management Co. (Global Investors) 22,565,030 7.30%
T. Rowe Price Associates, Inc. (Investment Management) 13,464,133 4.36%
Meditor Capital Management Ltd. 12,841,798 4.16%
BlackRock Fund Advisors 10,312,056 3.34%
Farallon Capital Management LLC 10,250,000 3.32%
Matrix Capital Management Co. LP 10,000,000 3.24%
SSgA Funds Management, Inc. 9,672,153 3.13%
AJO LP 7,636,882 2.47%
Company contact information
Exelixis, Inc.
1851 Harbor Bay
Alameda, CA 94502

Phone : +1.650.837.7000
Fax : +1.650.837.8300
Web : http://www.exelixis.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
EXELIXIS, INC.52.89%8 324
GILEAD SCIENCES, INC.0.09%81 542
VERTEX PHARMACEUTICALS23.98%70 706
REGENERON PHARMACEUTICALS50.47%59 455
WUXI APPTEC CO., LTD.46.78%33 392
GENMAB A/S59.57%24 520
BEIGENE, LTD.58.43%23 740
BIONTECH SE97.11%15 905
HUALAN BIOLOGICAL ENGINEERING INC.79.74%12 844
ARGENX SE41.78%11 340
SAREPTA THERAPEUTICS, INC.11.62%11 307
NEUROCRINE BIOSCIENCES, INC.-5.23%9 500
ASCENDIS PHARMA A/S4.74%7 752
MIRATI THERAPEUTICS, INC.25.69%7 214
BIOCON LIMITED50.56%7 120
MYOKARDIA, INC.78.69%6 903
ACCELERON PHARMA INC.96.59%6 243
ZAI LAB LIMITED94.35%6 053
PEPTIDREAM INC.-21.34%5 267
ULTRAGENYX PHARMACEUTICAL INC.92.98%4 994
ARROWHEAD PHARMACEUTICALS, INC.-27.87%4 680